Bellos I, et al. - In cirrhotic patients with refractory ascites, researchers ascertained if the response to treatment with tolvaptan was correlated with improved overall survival. The study sample consisted of 736 patients with cirrhosis and ascites. Sensitivity analysis suggested that the overall result of meta-analysis was not significantly affected by the presence of hepatocellular carcinoma, sample size, and study quality. Meta-analysis results support the prognostic role of tolvaptan response in patients with cirrhosis and refractory ascites, as overall survival has been shown to be significantly enhanced. Future large-scale studies should confirm these findings, while identifying efficient biomarkers to accurately predict response to tolvaptan and discriminate patients benefiting from its administration.